Sponsored studies carried out by IBDnet members

Efficacy and safety of Anthocyanin Rich Extract (ACRE) in moderate UC

Study drugs: Anthocyanin
Principal Investigators: Gerhard Rogler, USZ

Efficacy and safety of SHP-647, a MAdCAM1 inhibitor, in moderate to severe UC

Study drugs: SHP-647
Principal Investigators: Shire

Efficacy and safety of Risankizumab, a p19-selective IL-23 inhibitor, in moderate to severe CD and UC

Study drugs: Risankizumab
Principal Investigators: Abbvie

Efficacy and safety of Filgotinib, a JAK1-inhibitor, in moderate to severe CD

Study drugs: Filgotinib
Principal Investigators: Gilead

Efficacy and safety of Upadacitinib, a JAK1 inhibitor, in moderate to severe CD and UC

Study drugs: Upadacitinib
Principal Investigators: Abbvie